Toutes les Publications
- Safety issues and prospects for future generations of PPAR modulator
Anne Rubenstrunk, Rémy Hanf, Dean W. Hum, Jean-Charles Fruchart, Bart Staels
Biochimica et Biophysica Acta 1771 (2007) 1065–1081 - Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
Fruchart JC and Duriez P
Drugs Today (Barc), 2006, 42 (1), 39-64 - Sorting out the roles of PPARa in energy metabolism and vascular homeostasis
Lefebvre P, Chinetti G, Fruchart JC and Staels B
The Journal of Clinical Investigation, 2006, 116 (3), 571-581 - The Neuroprotective Effect of Atorvastatin in a Murine MCAO Model Is Dependent on PPARalpha
Sayah-Jeanne S, Bordet R, Laprais M, Poulain P, Coussaert A, Duriez P, Hanf R, Laskey R, Sasiela W, Hum D, Staels B and Fruchart JC
Stroke. 2006 Feb. 37(2)732, 2006, 37 (2), 732 - Pro-inflammatory cytokines IL-1, TNFa and IL-6 stimulate apolipoprotein A5 gene expression in mice through transactivation of a NF-KB p50 response element.
Genoux A, Helleboid-Chapman A, Dehondt H, Bauge E, Niculescu LS, Hum DW, Nowaka M, Jakel H, Martin G, Fruchart-Najib J and Fruchart JC
3rd Metabolic syndrome, Type II diabetes and Atherosclerosis congress, Marrakesh, May 24-28th 2006 - Transcriptional regulation of Apolipoprotein A5 gene expression by glucose through protein phosphatases signallingpathway and USF.
Nowak M, Helleboid-Chapman A, Jakel H, Moitrot E, Martin G, Pennacchio LA, Fruchart-Najib J and Fruchart JC
3rd Metabolic syndrome, Type II diabetes and Atherosclerosis congress, Marrakesh, May 24-28th 2006 - Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Simulatory Factor
Maxime Nowak, Audrey Helleboid-Chapman, Heidelinde Jakel, Geneviève Martin, Daniel Duran-Sandoval, Bart Staels, Edward M. Rubin, Len A. Pennacchio,Marja-Riitta Taskinen, Jamila Fruchart-Najib, Jean-Charles Fruchart
Molecular and Cellular Biology, Feb. 2005, p. 1537–1548 - Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulators With Angiotensin Receptor Blocking Activity.
Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U
Diabetes 54, 3442-3452, 2005 - Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene.
Gizard F, Robillard R, Gervois P, Faucompre A, Revillion F, Peyrat JP, Hum WD, Staels B
FEBS Letters 579, 5535-5541, 2005 - Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fievet C, Lefebvre P, Staels B
Arterioscler Thromb Vasc Biol., 25, 585-591, 2005 - TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1.
Gizard F, Robillard R, Barbier O, Quatannens B, Faucompre A, Revillion F, Peyrat JP, Staels B, Hum DW
Molecular and Cellular Biology, 25, 4335-4348, 2005 - Farnesoid X receptor represses hepatic lipase gene expression
Audrey Sirvent, Adrie J. M. Verhoeven, Hans Jansen, Vladimir Kosykh, Raphaël J. Darteil, Dean W. Hum, Jean-Charles Fruchart, Bart Staels
Journal of Lipid Research, 45, 2110-2115, 2004 - Glucose Regulates the Expression of the FarnesoidX Receptor in Liver.
Daniel Duran-Sandoval,1 Gisèle Mautino, Geneviève Martin, Frédéric Percevault, Olivier Barbier, Jean-Charles Fruchart, Folkert Kuipers, Bart Staels
Diabetes 53, 890-898, 2004 - Lesion Progression in apoE-Deficient Mice: Implication of Chemokines and Effect of the AT1 Angiotensin II Receptor Antagonist Irbesartan
Geneviève Martin, PhD, Frédérique Dol, PhD, Anne-Marie Marés, MSc, Vincent Berezowski, MSc, Bart Staels, PhD, Dean W. Hum, PhD, Paul Schaeffer, PhD, Jean-Marc Herbert, PhD
Journal of Cardiovascular Pharmacology, 43(2): 191-9, Feb 2004 - Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
Jamila Fruchart-Najib, Eric Baugé, Loredan-Stefan Niculescu, Tatiana Pham, Benoit Thomas,a Corinne Rommens, Zouher Majd, Bryan Brewer, Len A. Pennacchio,d and Jean-Charles Fruchart
Biochem Bio, Res commun, 25, 319(2)-397-404 - Pharmacodynamic and Phamacokinetic interaction between fenofibrate and ezetimibe
Teddy Kosoglou, Paul Statkevich, Jean-Charles Fruchart, Laura J. C. Pember, Larisa Reyderman, David L. Cutler, Michel Guillaume, Stephen E. Maxwell and Enrico P. Veltri
Current Medical Research and Opinion, 1197-1207, volume 20 N°8 - The farnesoid X receptor induces very low density lipoprotein receptor gene expression
Audrey Sirventa, Thierry Claudel, Geneviève Martin, John Brozek, Vladimir Kosykh, Raphaël Darteil, Dean W. Hum, Jean-Charles Fruchart, Bart Staels
FEBS Letters 566, 173–177, 2004 - The Liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREB-1c
Heidelinde Jakel, Maxime Nowak, Emanuelle Moitrot, Hé lène Dehondt, Dean W. Hum, Len A. Pennacchio, Jamila Fruchart-Najib, Jean-Charles Fruchart
The Journal of Biological Chemistry, vol 279, Issue 44, 45462-45469, October 2004 - The transcriptional regulating protein of 132 kDa (TReP-132) differentially influences steroidogenic pathways in human adrenal NCI-H295 cells
F Gizard, E Teissier, I Dufort, G Luc, V Luu-The, B Staels and D W Hum
Journal of Molecular Endocrinology, 32, 557-569, 2004 - FXR Induces the UGT2B4 Enzyme in Hepatocytes: A potential Mechanism of Negative Feedback Control of FXR Activity
Olivier Barbier, Ines Pineda Torra, Audrey Sirvent, Thierry Claudel, Christophe Blanquart, Daniel Duran–Sandoval, Folkert Kuipers, Vladimir Kosykh, Jean–Charles Fruchart, Bart Staels
Gastroenterology, 124, 1926-1940, 2003 - Lesion progression in apoE-deficient mice: implication ofchemokines and effect of the AT1 angiotensin II receptor antagonistirbesartan
Geneviève Martin, Frédérique Dol, Anne-Marie Marés, Vincent Berezowski, Bart Staels, Dean W. Hum, Paul Schaeffer and Jean-Marc HerbertJournal of Cardiovascular Pharmacology, 2003 - Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line
Antoine Pilon, Geneviève Martin, Stéphanie Bultel-Brienne, Didier Junquero, André Delhon, Jean-Charles Fruchart, Bart Staels, Véronique Clavey,
Biochimica et Biophysica Acta 1631 (2003) 218– 228 - Age-related phenotypes in the staggerer mouse expand the RORa nuclear receptor’s role beyond the cerebellum.
C.I. Jarvis, B. Staels, B. Brugg, Y. Lemaigre-Dubreuil, A. Tedgui, J. Mariani
Mol. Cell. Endocrinol., 2002, 186, 1-5. - Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription. via a negative FXR response element.
T. Claudel, E. Sturm, H. Duez, I. Pineda-Torra, A. Sirvent, V. Kosykh, J.C. Fruchart, J. Dallongeville, D.W. Hum, F. Kuipers, B. Staels
J. Clin. Invest., 2002, 109, 961-971. - Characterization of the human PPARa promoter : identification of a functional nuclear receptor response element.
I. Pineda-Torra, Y. Jamshidi, D.M. Flavell, J.C. Fruchart, B. Staels
Mol. Endocrinol., 2002, 16, 1013-1028. - DNA binding independent induction of IkBa gene transcription by PPARa.
P. Delerive, K. De Bosscher, W. Vanden Berghe, J.C. Fruchart, G. Haegeman, B. Staels
Mol. Endocrinol., 2002, 16, 1029-1039. - Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations and cholesterol efflux capacity.
M.T. Montoya, A. Porres, S. Serrano, J.C. Fruchart, P. Mata, J.A. Gomez-Gerique, G.R. Castro
Am. J. Clin. Nutr., 2002, 75/3, 484-491. - Function of the transcriptional regulating protein of 132 kDa (TReP-132) on human P450scc gene expression
Florence Gizard, Mohamed El-Alfy, Yannick Duguay, Bernard Lavallée, Fredérique DeWitte, Bart Staels, Barbara G. Beatty, Dean W. Hum
Endocrine Research, 28(4), 559-574, November 2002 - HMG-CoA reductase inhibition and PPARa activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.
A. Kandoussi, F. Martin, M. Hazzan, C. Noel, J.C. Fruchart, B. Staels, P. Duriez
Clinical Science, 2002, 102. - PPAR agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages.
F.G. Gbaguidi, G. Chinetti, D. Milosavljevic, E. Teissier, J. Chapman, G. Olivecrona, J.C. Fruchart, S. Griglio, J. Fruchart-Najib, B. Staels
FEBS Letters, 2002, 512, 85-90. - The Transcriptional Regulating Protein of 132 kDa (TReP-132) Enhances P450scc Gene Transcription through Interaction with Steroidogenic Factor-1 in Human Adrenal Cells
Florence Gizard, Bernard Lavallé, Frédérique DeWitte, Elisabeth Teissier, Bart Staels, Dean W.Hum
The Journal of Biological Chemistry, Vol. 277(42), 39144–39155, October 2002 - A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression
Florence Gizard, Bernard Lavallee, Frédérique Dewitte, Dean W. Hum
J. Biol. Chem., 276, 33881-33892, August 2001 - An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing.
L.A. Pennacchio, M. Olivier, J.A. Hubacek, J.C. Cohen, D.R. Cox, J.C. Fruchart, R.M. Krauss, E.M. Rubin
Science, 2001, 294, 169-173. - Angiotensin at1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein e-deficient mice.
F. Dol, G. Martin, B Staels, A.M. Mares, C Cazaubon, D Nisato, Jp Bidouard, Ph Janiak, P.Schaeffer And J.M. Herbert
J.Cardiovasc. Pharmacol. (2001) 38 : 395-405 - Current practice in the treatment of hyperlipidaemias.
P. Duriez
Expert Opin. Pharmacother., 2001, 2/11, 1777-1794. - Effects of dietary maritime pine seed oil on lipoprotein metabolism and atherosclerosis development in mice expressing human apolipoprotein B.
G. Asset, E. Bauge, R.L. Wolff, J.C. Fruchart, J. Dallongeville
Eur. J. Nutr., 2001, 40, 268-274. - Induction of the phospholipid transfer protein (PLTP) gene accounts for the HDL enlargement in mice treated with fenofibrate.
M. Bouly, D. Masson, B. Gross, X Jiang, C. Fievet, G. Castro, A.R. Tall, J.C. Fruchart, B. Staels, L. Lagrost, G. Luc
J. Biol. Chem., 2001, 276, 25841-25847. - Lack of triglyceride-lowering properties of fish oil in apolipoprotein E deficient mice.
G. Asset, E. Bauge, J.C. Fruchart, J. Dallongeville
Arterioscler. Thromb. Vasc. Biol., 2001, 21, 401-406. - Negative regulation of human fibrinogen gene expression by PPARa agonists via inhibition of C/EBPb.
P. Gervois, N. Vu-Dac, R. Kleemann, M. Kockx, G. Dubois, B. Laine, V. Kosykh, J.C. Fruchart, T. Kooistra, B. Staels
J. Biol. Chem., 2001, 276, 33471-33477. - New roles for PPARs in cholesterol homeostasis.
B. Staels
Trends Pharmacol. Sci., 2001, 22/9, 444. - Mechanisms of action of statins and fibrates.
J.C. Fruchart, P. Duriez
In : “Occlusive Arterial Disease : The interfaces among dyslipidemias, hypertension and diabetes”, Volume 4 of the New Horizon Series, Eds. C.J. Schwartz, G.V.R. Born, Schattauer GmbH
Stuttgart, 2001, pp101-116. - Negative regulation of human fibrinogen gene expression by PPARa agonists via inhibition of C/EBPb.
P. Gervois, N. Vu-Dac, R. Kleemann, M. Kockx, G. Dubois, B. Laine, V. Kosykh, J.C. Fruchart, T. Kooistra, B. Staels
J. Biol. Chem., 2001, 276, 33471-33477. - New roles for PPARs in cholesterol homeostasis.
B. Staels
Trends Pharmacol. Sci., 2001, 22/9, 444. - Overview : PPAR and cardiovascular risk.
J.C. Fruchart
J. Cardiovasc. Risk, 2001, 8/4 , 185-196. - Peroxisome proliferator-activated receptor a is not rate limiting for the lipoprotein lowering action of fish oil.
J. Dallongeville, E. Bauge, A. Tailleux, J.M. Peters, F.J. Gonzalez, J.C. Fruchart, B. Staels
J. Biol. Chem., 2001, 276, 4634-4639. - Peroxisome proliferator-activated receptors (PPARs) : nuclear receptors with functions in the vascular wall.
G. Chinetti, J.C. Fruchart, B. Staels
Z. Kardiol., 2001, 90, 125-132. - Peroxisome proliferator-activated receptors : from transcriptional control to clinical practice.
I. Pineda-Torra, G. Chinetti, C. Duval, J.C. Fruchart, B. Staels
Curr. Opin. Lipidol., 2001, 12, 245-254. - Peroxisome proliferator-activated receptors in inflammation control.
P. Delerive, J.C. Fruchart, B. Staels
J. Endocrinol., 2001, 169, 453-459. - PPAR-a activation and HDL metabolism.
J.C. Fruchart
Am. J. Cardiol., 2001, Suppl. 88, 24N-29N. - PPAR-a agonists inhibit tissue factor expression in human monocytes and macrophages.
B.P. Neve, D. Corseaux, G. Chinetti, C. Zawadzki, J.C. Fruchart, P. Duriez, B. Staels, B. Jude
Circulation, 2001, 103, 207-212. - PPAR-a and PPAR-g activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.
G. Chinetti, S. Lestavel, V. Bocher, A.T. Remaley, B. Neve, I. Pineda Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H.B. Brewer, J.C. Fruchart, V. Clavey, B. Staels
Nature Medicine, 2001, 7, 53-58. - PPARa-null mice are protected from high-fat diet-induced insulin resistance.
M. Guerre-Millo, C. Rouault, P. Poulain, J. André, V. Poitout, J.M. Peters, F.J. Gonzalez, J.C. Fruchart, G. Reach, B. Staels
Diabetes, 2001, 50, 2809-2814. - PPARs in inflammation, atherosclerosis and thrombosis.
H. Duez, J.C. Fruchart, B. Staels
J. Cardiovasc. Risk, 2001, 8/4 , 187-194. - PPARs, metabolic disease and atherosclerosis.
J.C. Fruchart, B. Staels, P. Duriez
Pharmacol. Res., 2001, 44, 345-352. - Regulation of lipid and lipoprotein metabolism by retinoids.
B. Staels
J. Am. Acad. Dermatol., 2001, 45, S158-S167. - Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apo A-I.
G. Martin, H. Duez, C. Blanquart, V. Berezowski, P. Poulain, J.C. Fruchart, J. Najib-Fruchart, C. Glineur, B. Staels
J. Clin. Invest., 2001, 107, 1423-1432. - The orphan nuclear receptor RORa is a negative regulator of the inflammatory response.
P. Delerive, D. Monte, G. Dubois, F. Trottein, J. Fruchart-Najib, J. Mariani, J.C. Fruchart, B. Staels
EMBO Reports, 2001, 2, 42-48. - The role of fibric acids in atherosclerosis.
J.C. Fruchart, B. Staels, P. Duriez
Curr. Atheroscler. Rep., 2001, 3, 83-92. - Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORa.
E. Raspe, H. Duez, P. Gervois, C. Fievet, J.C. Fruchart, S. Besnard, J. Mariani, A. Tedgui, B. Staels
J. Biol. Chem., 2001, 276, 2865-2871. - Are nuclear factors the ultimate targets of drugs affecting lipid metabolism ?
J.C. Fruchart
Current Atherosclerosis Reports, 2000, 2, 353-354. - CLA-1/SR-B1 is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors (PPARs).
G. Chinetti, F.G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci, P. Poulain, J. Chapman, J.C. Fruchart, A. Tedgui, J. Najib-Fruchart, B. Staels
Circulation, 2000, 101, 2411-2417. - Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer selective rexinoids suggests that the PPAR-RXR heterodimer is their molecular target.
G. Martin, H. Poirier, N. Hennuyer, D. Crombie, J.C. Fruchart, R.A. Heyman, P. Besnard, J. Auwerx
J. Biol. Chem., 2000, 275 , 12612-12618. - Is there still a place for the fibrates ?
P. Duriez, J.C. Fruchart
In : “Lipids and Vascular Disease”, Current Issues, Ed. D.J. Betteridge, Martin Dunitz
Publishers Ltd, 2000, pp 219-234. - Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry.
L. Beghin, N. Duhal, P. Poulain, P. Hauw, B. Lacroix, J.M. Lecerf, J.P. Bonte, J.C. Fruchart, G. Luc
J. Lipid Res., 2000, 41, 1172-1176. - Nuclear transcription factors : new opportunities for lipid lowering.
B. Staels
Proc. Nutr. Soc., 2000, 59, 433. - Peroxisome proliferator-activated receptors (PPARs) : nuclear receptors at the crossroads between lipid metabolism and inflammation.
G. Chinetti, J.C. Fruchart, B. Staels
Inflamm. Res., 2000, 49, 497-505. - Potential role of drug combinations in the prevention of cardiovascular disease.
J.C. Fruchart, P. Duriez
Eur. Heart J. Supplements, 2000, 2, D54-D56. - PPAR activation – enhancing the protective power of HDL-C.
J.C. Fruchart
Clinician, 2000, 18, 19-23. - PPARa activators improve insulin sensitivity and reduce adiposity.
M. Guerre-Millo, P. Gervois, E. Raspe, L. Madsen, P. Poulain, B. Derudas, J.M. Herbert, D.A. Winegar, T.M. Willson, J.C. Fruchart, R.K. Berge, B. Staels
J. Biol. Chem., 2000, 275, 16638-16642. - Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
B.P. Neve, J.C. Fruchart, B. Staels
Biochem. Pharmacol., 2000, 60, 1245-1250. - The human fatty acid transport protein-1 (SLC27A1; FATP-1) cDNA and gene : organization, chromosomal localization, and expression.
G. Martin, M. Nemoto, L. Gelman, S. Geffroy, J. Najib, J.C. Fruchart, P. Roevens, B. De Martinville, S. Deeb, J. Auwerx
Genomics, 2000, 66, 296-304.66, - The PPAR system and regulation of lipoprotein metabolism.
B. Staels
In : “Lipids and Vascular Disease”, Current Issues, Ed. D.J. Betteridge,
Martin Dunitz Publishers Ltd, 2000, pp 27-37. - A truncated human PPARa splice variant with dominant negative activity.
P. Gervois, I. Pineda-Torra, G. Chinetti, T. Grotzinger, G. Dubois, J.C. Fruchart, J. Fruchart-Najib, E. Leitersdorf, B. Staels
Mol. Endocrinol., 1999, 13, 1535-1549. - An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer.
L. Gelman, J.C. Fruchart, J. Auwerx
Cell. Mol. Life Sci., 1999, 55, 932-943. - Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.
N. Hennuyer, P. Poulain, L. Madsen, R.K. Berge, L.M. Houdebine, D. Branellec, J.C. Fruchart, C. Fievet, N. Duverger, B. Staels
Circulation, 1999, 99, 2445-2451. - Comparison of expression and regulation of the high density lipoprotein receptor SR-BI and the LDL-receptor in human adrenocortical carcinoma NCI-H295 cells.
G. Martin, A. Pilon, C. Albert, M. Valle, D.W. Hum, J.C. Fruchart, J. Najib, V. Clavey, B. Staels
Eur. J. Biochem., 1999, 261, 481-491. - Coronary heart disease : reducing the risk : a worldwide view.
G. Assmann, R. Carmena, P. Cullen, J.C. Fruchart, F. Jossa, B. Lewis, M. Mancini, R. Paoletti
Circulation, 1999, 100, 1930-1938. - Developmental and pharmacological regulation of apolipoprotein C-ll gene expression. Comparison with apo C-l and apo C-III gene regulation.
Y. Andersson, Z. Majd, A.M. Lefebvre, G. Martin, A.V. Sechkin, V. Kosykh, J.C. Fruchart, J. Najib, B. Staels.
Artherioscler. Thromb. Vasc. Biol., 1999, 19, 115-121. - Effects of pinus pinaster and pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat.
G. Asset, B. Staels, R.L. Wolff, E. Bauge, Z. Madj, J.C. Fruchart, J. Dallongeville
Lipids, 1999, 34, 39-44. - Fibrates increase human Rev-Erba expression in liver via a novel PPAR response element.
P. Gervois, S. Chopin-Delannoy, A. Fadel, G. Dubois, V. Kosykh, J.C. Fruchart, J.Najib, V. Laudet, B. Staels
Mol. Endocrinol., 1999, 13/3, 400-409. - P300 interacts with the N- and C- terminal part of PPARg2 in a ligand-independent and dependent manner, respectively
L. Gelman, G. Zhou, L. Fajas, E. Raspe, J.C. Fruchart, J. Auwerx
J. Biol. Chem., 1999, 274, 7681-7688. - PPARa activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.
J.C. Fruchart, P. Duriez, B. Staels
Current Opinion in Lipidology, 1999, 10, 245-257. - Recent developments in the treatment of hypertriglyceridemia.
P. Duriez, j.c. Fruchart
Current Atherosclerosis Reports, 1999, I, 31-37. - Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier.
C. Fillebeen, L. Descamps, M.P. Dehouck, L. Fenart, M. Benaissa, G. Spik, R.Cecchelu, A. Pierce
J. Biol. Chem., 1999, 274, 7011-1017. - Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/Sterol regulatory element binding protein 1 : implications for adipocyte differentiation and metabolism.
L. Fajas, K. Schoonjans, L. Gelman, J.B. Kim, J. Najib, G. Martin, J.C. Fruchart, M. Briggs, B.M. Spiegelman, J. Auwerx
Mol Cell Biol, 1999, 19, 5495-5503. - Somatic gene transfer of human apo A-l inhibits atherosclerosis progression in mouse models.
P. Benoit, F. Emmanuel, J.M. Caillaud, L. Bassinet, G. Castro, P. Galux, J.C. Rnfruchart, D. Branellec, P. Denefle, N. Duverger
Circulation, 1999, 99, 105-110. - 17ß-estradiol prevents fatty streak formation in apolipoprotein E-deficeint mice.
R. Elhage, J.F. Arnal, M.T. Pieraggi, N. Duvergre, C.Fievet, J.C. Faye, F. Bayard.
Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2679-2684. - A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans.
A. Meirhaeghe, L. Fajas, N. Helbecque, D. Cottel, P. Lebel, J. Dallongeville, S. Deeb, J. Auwerx, P. Amouyel.
Hum. Mol. Genet., 1998, 3, 435-440. - A Pro12Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.
S.S. Deeb, L. Fajas, M. Nemoto, J. Pihlajamaki, L. Mykkanen, J. Kuusisto, M. Laakso, W. Fujimoto, J Auwerx.
Nature Genetics, 1998, 20, 284-287. - Activation of human aortic smooth-muscle cells is inhibited by PPAR&#a but no by PPARg activator.
B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret, I. Pineda Torra, P. Delerive, A. Fadel, G. Chinetti, J.C. Fruchart, J. Najib, J. Maclouf, A.Tedgui
Nature, 1998, 393, 790-793 - Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.
G. Chinetti, S. Griglio, M. Antonucci, I. Pineda-Torra, P. Delerive, Z. Majd, J.C. Fruchart, J.Chapman, J. Najib, B. Staels
J. Biol. Chem., 1998, 273, 25573-25580. - Activation of the peroxisome proliferator-actived receptor gamma promotes the development of colon tumors in mice.
A.M. Lefebvre, I. Chen, P. Desreumaux, J. Najib, J.C. Fruchart, K. Geboes, M. Briggs, R. Heyman, J. Auwerx.
Nature Medicine, 1998, 4, 1053-1057. - Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients.
M. Arnadotir, A.L. Berg, J. Dallongeville, J.C. Fruchart, P. Nilsson-Ehle.
Kidney Int., 1997, 52, 1651-1655. - Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice.
J.M. Peters, N. Hennuyer, B. Staels, J.C. Fruchart, C. Fievet, F.J.Gonzales, J. Auwerx.
J. Biol. Chem., 1997, 272, 37307-27312. - Antipeptide antibodies discriminate between different SAA proteins in human plasma.
R. Saile, G. Hocke, A. Tartar, J.C. Fruchart, A. Steinmetz.
Biochim. Biophys. Acta, 1989, 992, 407-408. - Apolipoprotein A-I containing particles and reverse cholesterol transport in IDDM.
C. Fievet, N. Theret, N. Shojaee, P. Duchateau, G. Castro, G. Ailhaud, P. Drouin, J.C. Fruchart
Diabetes, 1992, 41/2, 81-85. - Cholesterol efflux from cultured adipose cells is mediated by LpA-I particles but not by LpA-I:A-II particles.
R. Barbaras, p. Puchois, j.c. Fruchart, g. Ailhaud
Biochem. Biophys. Res. Com., 1987, 142/1, 63-69. - Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid.
L. Lindstedt, M. Lee, G.R. Castro, J.C. Fruchart, P.T. Kovanen
J. Clin. Invest., 1996, 97/10, 2174-2182. - Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease.
J.C. Fruchart, H.B. Brewer Jr, E. Leitersdorf and the members of the Fibrate Consensus Group.
Am. J. Cardiol., 1998, 81, 912-917. - Coordinate regulation of the expression of the fatty acid transport protein and acyl CoA synthetase genes by PPARa And PPARc activators.
G. Martin, K. Schoonjans, A.M. Lefebvre, B. Staels, J. Auwerx.
J. Biol. Chem., 1997, 272, 28210-28217. - Endothelial derived vasorelaxation is impaired in human apo A-l transgenic rabbits.
G. Lebuffe, A. Boullier, A. Tailleux, B. Delfl Y, B. Dupuis, J.C Fruchart, N. Duverger, F. Emmanuel, P. Denefle, B. Vallet, P. Duriez.
Biochem. Biophys. Res. Com., 1997, 241, 205-211. - Expression of the peroxisome proliferator-activasted receptor gamma (PPARc) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.
M. Ricote, J. Huang, L. Fajas, A. Li, J. Welch, J. Najib, H.L. Witztum, J. Auwerx, W. Palinski, C.K. Glass.
Proc. Atl. Acad. Sci., 1998, 95, 7614-7619. - Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.
B. Staels, N. Vu-Dac, V.A. Kosykh, R. Saladin, J.C. Fruchart, J. Dallongeville, J. Auwerx
J. Clin. Invest., 1995, 95, 705-712. - Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
N. Vu-Dac, K. Schoonjans, V. Kosykh, J. Dallongeville, J.C. Fruchart, B. Staels, J. Auwerx
J. Clin. Invest., 1995, 96, 741-750. - Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apoliporpotein E-deficient mice.
H. Mezdour, R. Jones, C. Dengremont, G. Castro, N. Maeda.
J. Biol. Chem., 1997, 272, 13570-13575. - Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells.
A. Steinmetz, R. Barbaras, N. Ghalim, V. Clavey, J.C. Fruchart, G. Ailhaud
J. Biol. Chem., 1990, 265/14, 7859-7863. - Immunochemical characterization of two antigenic sites on human apolipoprotein A-I. Localization and lipid modulation of these epitopes.
F. Pio, H. De Loof, N. Vu Dac, V. Clavey, J.C. Fruchart, M. Rosseneu.
Biochim. Biophys. Acta, 1988, 959, 160-168. - In vivo glucosylated LpA-l subfraction. Evidence for structural and fonctionnal alterations.
B. Igau, G. Castro, V. Clavey, C. Slomianny, R.Bresson, P. Drouin, J.C Fruchart, C. Fievet.
Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2830-2836. - In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I:A-II.
D.J. Rader, G. Castro, L.A. Zech, J.C. Fruchart, H.B. Brewer
J. Lipid Res., 1991, 32, 1849-1859. - Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits.
N. Duverger, H. Kruth, F. Emmanuel, J.M. Caillaud, C. Viglietta, G. Castro, A. Tailleux, C. Fievet, J.C. Fruchart, L.M. Houdebine, P. Denefle
Circulation, 1996, 94, 713-717. - Inhibitory effects of specific apoliporpotein C-lll isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
C.J. Mann, A.A. Troussard, F.T. Yen, N.Annouche, J.Najib, J.C. Fruchart, V. Lotteau. P. Andre, B.E. Bihain
J. Biol. Chem., 1997, 272, 31348-31354. - Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (apo A-I) variants with murine adipocytes and macrophages : evidence for reduced cholesterol efflux promotion by apo A-I (Pro165 ® Arg).
A. Von Eckardstein, G. Castro, I. Wybranska, N. Theret, P. Duchateau, N. Duverger, J.C. Fruchart, G. Ailhaud, G. Assmann
J. Biol. Chem., 1993, 268/4, 2616-2622. - Interactions between lifestyle-related factors and the apo E polymorphism on plasma lipids and apolipoproteins. The EARS studies.
J. Boer, C. Ehnholm, H.J. Menzel, L. Ha Vekes, M. Rosseneu, D. O’reill Y, L. Tiret For The Ears Group.
Artherioscler. Thromb. Vasc. Biol., 1997, 17 1675-1681. - Interstitial fluid apolipoprotein A-II : an association with the occurence of myocardial infarction.
G. Luc, z. Majd, p. Poulain, l. Elkhalil, j.c. Fruchart
Atherosclerosis, 1996, 127, 131-137. - Isolation and characterization of human LpB lipoprotein containing apolipoprotein B as the sole apolipoprotein.
J.M.Bard, L. Candelier, G. Agnani, V. Clavey, G. Torpier, A. Steinmetz, J.C. Fruchart.
Biochim Biophys. Acta, 1991, 1082, 170-176. - Low-density lipoprotein receptors on endothelium of brain capillaries.
S. Meresse, C. Delbart, J.C. Fruchart, R. Cecchelli
J. Neurochem., 1989, 53, 340-345. - Mechanism of action of fibrates on lipid and lipoprotein metabolism.
Circulation, 1998, 98, 2088-2093 - On behalf of the European Atherosclerosis Resaerch Study (EARS) Group. Hepatic lipase gene polymorphisms influence plasma HDL levels. Results from Finnish EARS participants.
S. Murtomaki, E. Tahvanainen, M. Antikainen, L. Tiret, V. Nicaud H. Jansen, C. Ehnholm.
Arterioscler. Thromb. Vasc. Biol., 1997, 17 1879-1884. - Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
L. Berthou, N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx, A. Guillouzo, J.C. Fruchart, E. Rubin, P. Denefle, B. Staels, D. Branellec
J. Clin. Invest., 1996, 97, 2408-2416. - Peroxisome proliferator-activated receptors, orphans with ligands and functions.
K. Schoonjans, G. Martin, B. Staels, J. Auwerx.
Curr. Opin. Lipidol., 1997, 8, 159-166. - Postprandial dyslipidemia : a risk factor for coronary heart disease.
J. Dallongeville, J.C. Fruchart
Ann. Nutr. Metab., 1998, 42, 1-11. - Prevention of fatty strek formation of 17ß-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice.
R. Elhage, F. Bayard, V. Richard, P. Holvoet, N. Duverger, C. Fievet, J.F. Arnal.
Circulation, 1997, 96, 3048-3052. - Protection against atherogenesis in mice mediated by human apolipoprotein A-IV.
N. Duverger, G. Tremp, J.M. Caillaud, F. Emmanuel, G. Castro, J.C. Fruchart, A. Steinmetz, P. Denefle
Science, 1996, 23, 966-968. - Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.
N. Vu-Dag, P. Gervois, I. Pineda-Torra, J.C. Fruchart, V. Kosykh, T. Kooistra, H.M.G. Princen, J. Dallongeville, B. Staels.
J. Clin. Invest., 1998, 101 , 625-632. - Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyse atherogenic lipoprotein at neutral pH.
J. Auwerx, B. Staels. Leptin. Lancet, 1998, 351, 737-742.Rn50. S.L. Schissel, X.C. Jiang, J. Tweedie-Hardman, T.S Jeong, E.H. Camejo, J. Najib, J.H. Rapp, K.J. Williams, I. Tabas
Proc. Atl. Acad. Sci., 1998, 95, 7614-7619. - Severe atherosclerosis and hypoalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORa.
A. Mamontava, S. Seguret-Mace, B. Esposito, C. Chaniale, M. Boul Y, N. Delhaye-Bouchaud, G. Luc, B. Staels, N. Duverger, J. Mariani, A. Tedgui.
Circulation, 1998, 98, 2738-2743. - Structural properties of high density lipoprotein subclasses homogeneous in protein composition and size.
A. Leroy, K.L. Harms Toohill, J.C. Fruchart, A. Jonas
J. Biol. Chem., 1993, 268/7, 4798-4805. - Targeted replacement of the mouse apolipoprotein E gene with the common human apoE3 allele enhances diet-induced hypercholesterolemia and atheorosclosis.
P.M. Sullivan, H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R.L. Reddick, S.H. Quarfordt, N. Maeda.
J. Biol. Chem., 1997, 272, 17972-17980. - The human PPARg gene : organization, promoter analysis, and expression.
L. Fajas, D. Auboeuf, E. Raspe, K. Schoonjans, A.M. Lefebvre, R. Saladin, J. Najib, M. Laville, J.C. Fruchart, S. Deeb, A. Puig-Vidal, J. Flier, M.R. Briggs, H. Vidal, B. Staels, J. Auwerx
J. Biol. Chem., 1997, 272, 18779-18789. - The nuclear receptors PPARa and rev-erba mediate the species regulation of apolipoprotein A-l expression by fibrates.
N. Vu-Dac, S. Chopin-Delannoy, P. Gervois, E. Bonnelye, G. Martin, J.C. Fruchart, V. Laudet, B. Staels.
J. Biol. Chem., 1998, 273, 25713-25720. - The role of a triplet repeat sequence of the very low density lipoprotein receptor gene in plasma lipid and lipoprotein level variability in humans.
N. Helbecque, J. Daloongeville, V. Codron, D. Arveiler, J.B. Ruidavets, A. Evans, F. Cambien, J.C Fruchart, P. Amouyel.
Arterioscler. Thromb. Vasc. Biol. ,1997, 17, 2759-2764. - Transcriptional control of adipogenesis.
L. Fajas, J.C. Fruchart, J. Auwerx.
Curr. Opin. Cell Biol., 1998, 10,165-173. - Transcriptional control of triglyceride metabolism : fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.
J. Auwerx, K. Schoonjans, J.C. Fruchart, B. Staels
Atherosclerosis, 1996, 124, S29-S37. - Transient increase in obese gene expression after food intake or insulin administration.
R. Saladin, P. De Vos, M. Guerre-Millo, A. Leturque, J. Girard, B. Staels, J. Auwerx
Nature, 1995, 377, 527-529.
